findmyKOL
Clinical trialNCT03113643RecruitingPhase 1Interventional

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

SponsorDana-Farber Cancer InstituteEnrollment72Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic Syndrome
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • City of Hope

    Duarte, California, United States

    Anthony Stein, MD
    Recruiting
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Andrew Lane, MD, PhD
    Recruiting
  • Md Anderson Cancer Center

    Houston, Texas, United States

    Naveen Pemmaraju, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →SL-401 →Venetoclax →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Jun 2017
Primary completion
15 Sept 2021
Completion
31 May 2027
Last update posted
17 Jun 2026
Registered enrollment
72
Registry id
NCT03113643
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.